Key result
Impaired cyclic nucleotide signaling and phosphodiesterase activity contribute to cardiac sympathetic overactivity in hypertension.
Targeting impaired cyclic nucleotide signaling and phosphodiesterase activity may offer novel therapeutic approaches for managing sympathetic overactivity in hypertension and heart failure.
Does not support practice change in hypertension; leaves open clinical translation of cyclic nucleotide targets pending trials.
Cardiac sympathetic overactivity is a well-established contributor to the progression of neurogenic hypertension and heart failure, yet the underlying pathophysiology remains unclear. Recent studies have highlighted the importance of acutely regulated cyclic nucleotides and their effectors in the control of intracellular calcium and exocytosis. Emerging evidence now suggests that a significant component of sympathetic overactivity and enhanced transmission may arise from impaired cyclic nucleotide signalling, resulting from compromised phosphodiesterase activity, as well as alterations in receptor-coupled G-protein activation. In this review, we address some of the key cellular and molecular pathways that contribute to sympathetic overactivity in hypertension and discuss their potential for therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Bardsley et al. (2018) conducted a review in Neurogenic hypertension and heart failure. Impaired cyclic nucleotide signaling and compromised phosphodiesterase activity contribute to cardiac sympathetic overactivity in hypertension and represent potential targets for therapeutic intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: